Clinical Trial Update: Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating preoperative pembrolizumab for colorectal cancer with resectable liver metastases was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Chloe Atreya, MD, PhD | Conditions: Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8 | Phase 2 | Status: TERMINATED | Results posted: 2025-12-31